Johnson & Johnson

Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA

18 Dec 2024

The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an autologous stem cell transplant, followed by 24 months f

Johnson & Johnson Participates in the Inauguration of World Health Organization (WHO) Academy to Improve Training and Education of Health Workers Globally

17 Dec 2024

J&J made a $7 million grant to the Institut de France which will help the WHO Academy provide both online and in-person educational opportunities for health workers throughout their careers Training,

Update on U.S. regulatory review of subcutaneous amivantamab

17 Dec 2024

Johnson & Johnson submits application seeking U.S. FDA approval of SIMPONI

16 Dec 2024

Submission aims to expand SIMPONI ulcerative colitis indication to include pediatric population

Johnson & Johnson to Participate in the 43

13 Dec 2024

U.S. FDA Expands Indication for Impella Heart Pumps to Treat Pediatric Patients

12 Dec 2024

Impella 5.5 and Impella CP are the first left-sided, minimally invasive temporary mechanical circulatory support options for pediatric patients with symptomatic ADHF and cardiogenic shock

Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options

11 Dec 2024

Abstracts presented at ASH 2024 provide insight into the patient experience given the unpredictable nature of wAIHA, a rare autoantibody disease, and the uncertainty of current treatment approaches us

Johnson & Johnson MedTech Joins Experts to Define and Classify Surgical Site Outcomes

06 Dec 2024

Healthcare experts call for consistent definitions in the assessment, reporting, and monitoring of surgical wounds A standardized classification system offers potential to capture and treat underrepor

Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA

02 Dec 2024

Applications filed for TREMFYA® to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic arthritis

MENTOR™ MemoryGel™ Enhance Breast Implant Receives FDA Approval for Largest Size Breast Implants for Reconstruction

02 Dec 2024

MemoryGel™ Enhance Breast Implant is the first and only implant line created specifically for women with larger breast cup sizes undergoing breast reconstruction and reconstruction revision ATHENA Stu